Raphael Pharmaceutical (RAPH) Return on Capital Employed (2021 - 2024)
Raphael Pharmaceutical (RAPH) posted Return on Capital Employed of 206.71% for Q4 2024, up 21.69% sequentially from 169.87% in Q3 2024, and up 87973.0% YoY from N/an in Q1 2024.
Raphael Pharmaceutical (RAPH) Return on Capital Employed (2021 - 2024) Analysis & Trends
Raphael Pharmaceutical has reported Return on Capital Employed for 4 years, with the latest figure at 206.71% in Q4 2024.
- Quarterly Return on Capital Employed rose 87973.0% year-over-year to 206.71% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 206.71% (up 87973.0% YoY) and the FY2025 annual result came in at 86.1%, down 15116.0% from the prior year.
- Return on Capital Employed rose to 206.71% in Q4 2024 per RAPH's latest filing, from 169.87% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11375.51% in Q3 2022 and troughed at 4121.21% in Q1 2023.
- A 4-year average of 1478.73% and a median of 495.19% in 2024 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 866562 bps in 2023, down 1021883 bps in 2023.
- Over 4 years, Return on Capital Employed stood at 3132.69% in 2021, then jumped by 263 bps to 11375.51% in 2022, then plunged by 106 bps to 673.02% in 2023, then soared by 131 bps to 206.71% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 206.71%, 169.87%, and 783.66% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 65.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 206.71% |
| Sep 30, 2024 | 169.87% |
| Jun 30, 2024 | 783.66% |
| Mar 31, 2024 | 975.63% |
| Dec 31, 2023 | -673.02% |
| Sep 30, 2023 | 1,156.68% |
| Jun 30, 2023 | 7,048.35% |
| Mar 31, 2023 | -4,121.21% |
| Sep 30, 2022 | 11,375.51% |
| Jun 30, 2022 | -1,617.27% |
| Mar 31, 2022 | -692.86% |
| Dec 31, 2021 | 3,132.69% |